BackSummit Therapeutics Overview

Summit Therapeutics Selling, General & Admin

Explore Summit Therapeutics's selling, general & admin with historical charts and peer comparisons.

Get informed when a big investor buys or sells

+ Follow

Quarterly SG&A Expenses

$62.76M
82.58% YoY

As of Jun 30, 2026

Annual SG&A Expenses (TTM)

$306.14M
25.47% YoY

Trailing 12 months ending Jun 30, 2026

Average SG&A Expenses (Comparison Companies)

Selling, General & Admin History

Selling, General & Admin Comparison

Annual Selling, General & Admin Growth Rate (%)

Annual Selling, General & Admin Growth (Absolute)

Summit Therapeutics (SMMT) FAQ

Stockcircle tracks selling, general & admin for Summit Therapeutics (SMMT), including historical charts and peer comparisons when data is available. Check back as new filings are published, or open the stock overview for a broader fundamental snapshot.

This Selling, General & Admin page is built for Summit Therapeutics's historical SG&A expenses trend and peer context. When enough reporting periods are on file, the charts below visualize how the metric has moved over time.

Use SG&A expenses as one input alongside growth, profitability, valuation, and ownership activity. Stockcircle links related metric pages and the main SMMT overview so you can move from this figure to the surrounding analysis quickly.